65 98. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52:561-571 99. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J. C-reactive protein in the arterial int<strong>im</strong>a: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-2099 100. van Leeuwen MA, van der Heijde DMFM, van Rijswijk MH et al. Interrelationschip of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994;21:425-429 101. Volanakis JE. Review: Human C-reactive protein: expression, structure, and function. Mol Immunol 2001;38:189-197 102. Wechsel HW, Feil G, Lahme S, Zumbraegel A, Petri E, Bichler KH. Control of hepatic parameters in renal cell carcinoma (RCC) by interleukin-6 (IL-6)?. Anticancer Res 1999;19:2577-2581 103. Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KC. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 2001;88:255-260 104. Wu CW, Wang SR, Chao MF et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996;91:1417-1422 105. Xing Z, Gauldie J, Cox G et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101:311- 320 106. Yasoj<strong>im</strong>a K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158:1039-1051 107. Yasoj<strong>im</strong>a K, Schwab C, McGeer EG, McGeer PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzhe<strong>im</strong>er’s disease. Brain Res 2000;887:80-89 108. Yoshida N, Ikemoto S, Narita K, Sug<strong>im</strong>ura K, Wada S, Yasumoto R, Kish<strong>im</strong>oto T, Nakatani T. Interleukin-6, tumour necrosis factor-α and interleukin-1β in patients with renal cell carcinoma. Br J Cancer 2002;86:1396-1400 109. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: <strong>im</strong>plications for atherosclerosis. Circulation 2001;103:1194-1197
Tabelle A: Prä- und perioperative Charakteristika der 40 Nierenkarzinompatienten Patient Alter Geschl. Tumorgröße Histologie Tumorstadium Grading Plasma-CRP präop Leukozytenzahl U-Kultur Plasma-CRP postop (Jahre) (cm) T G (mg/l) (/nl) (mg/l) 1 64 m 7 klar 2 2 40 6,2 neg. n.b. 2 69 m 10,3 klar 3a 1 10 10,3 neg. 6 3 60 m 2,5 klar 1 2 18 7,7 neg. 64 5 65 m 7,1 klar 2 2 7 8,1 n. b.